Tumors don't have chance to adapt if DCs can present hundreds of tumor-associated antigens to immune system. The current issue is that with massive t-cell infiltration into tumor site comes tumor-associated macropahges which can be depleted by CSF1R inhibitor. The CD163hi macrophage issue is so minor in comparison of massive and sustainable t-cell infiltration triggered by DCVax-L.
Market Data 
Markets 
AI
